Pharmacological inhibition of CDC42 in HG-3, PGA-1, or JVM-3 cells could not further reduce the small subpopulation of CLL cells with an AR in these cell lines (Figure 3A, right and Supplementary Figure S3A) and had accordingly no effect on their already highly susceptible phenotype (Figure 3B, right and Supplementary Figure S3B). This evidence concerns the gene AR and B-cell chronic lymphocytic leukemia.